Gapping up
In reaction to strong earnings/guidance:
- SCPL +15.2%, CLFD +14.4%, BJRI +11.6%, ECOM +10.8%, LMAT +9.6%, SKX +7.9%, SGMS +5.3%, MXL +4.9%, EW +4.8%, TPH +4.1% (light volume), MANH +4%, MAT +3.4%, SAM +3.2%, BLMN +3%, FE +2.6%, FBNC +1.9%, AUY +1.7%, FWRD +1.5%
M&A news:
- SWIR +18.3% (to divest China-based automotive embedded module product line for US$165 mln)
Other news:
- THTX +24.2% (announces new data supporting the potential role of tesamorelin in the treatment of HIV-associated NASH)
- ABUS +17.1% (continued strength on favorable patent ruling; also downgraded to Neutral from Outperform at Robert W. Baird)
- RDUS +9.4% (announces license agreement with Menarini Group to develop/commercialize elacestrant)
- AMD +6.8% / TSM +3.3% (possible beneficiaries to Intel delay; also TSM was upgraded at Macquarie)
- ADAP +5.7% (European Medicines Agency grants access to PRIME initiative for ADP-A2M4 for synovial sarcoma)
- GS +1.6% (reaches agreement with Malaysia to drop all criminal charges in exchange for $3.9 bln in reparations, according to Bloomberg)
- CMCSA +1.4% (still checking; may be attributed reports of strong TV ad growth for streaming services)
- ARCT +1.1% (confirms binding term sheet with Israel to supply COVID-19 vaccine candidate),
- WABC +1% (approves plan to repurchase up to 1.75 mln shares),
- AZN +1% (Breztri Aerosphere approved in the US for the maintenance treatment of COPD)
- VSAT +0.9% (closes of $175 mln strategic common stock investment)
Analyst comments:
- COP +2.8% / CVX+0.3% (initiated with Buy at SunTrust)
- NCNA +2.3% (initiated with Outperform at Oppenheimer)
- HSY +0.6% (upgraded to Outperform at Evercore ISI)
- ADS +0.5% (upgraded to Buy at BofA Securities)
- JPM +0.5% (upgraded to Buy from Neutral at Goldman)
- CVS +0.2% (upgraded to Outperform from Sector Perform at RBC Capital)